TuHURA Biosciences (HURA) Income from Non-Controlling Interests (2011 - 2026)
TuHURA Biosciences (HURA) posted quarterly Income from Non-Controlling Interests of $2000.0 for Q1 2026, little changed quarter-over-quarter from $2000.0 in Q4 2025.
TuHURA Biosciences (HURA) Income from Non-Controlling Interests (2011 - 2026) Analysis & Trends
TuHURA Biosciences' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at $2000.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests changed N/A year-over-year to $2000.0; the TTM figure through Mar 2026 stood at -$10903.0 (changed N/A YoY), while the FY2025 annual figure was $5000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $2000.0, roughly flat from $2000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $3000.0 in Q3 2025, with the low at $2000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Mar 31, 2012 | -17,903.00 |
| Mar 31, 2011 | -3,890.00 |